Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
Crossref DOI link: https://doi.org/10.1007/s00277-017-2994-x
Published Online: 2017-04-30
Published Print: 2017-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Vannucchi, Alessandro Maria
Verstovsek, Srdan
Guglielmelli, Paola
Griesshammer, Martin
Burn, Timothy C.
Naim, Ahmad
Paranagama, Dilan
Marker, Mahtab
Gadbaw, Brian
Kiladjian, Jean-Jacques
License valid from 2017-04-30